0001437749-24-018624.txt : 20240529 0001437749-24-018624.hdr.sgml : 20240529 20240529175818 ACCESSION NUMBER: 0001437749-24-018624 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240524 FILED AS OF DATE: 20240529 DATE AS OF CHANGE: 20240529 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lorrain Daniel S. CENTRAL INDEX KEY: 0001861550 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42001 FILM NUMBER: 241000011 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Contineum Therapeutics, Inc. CENTRAL INDEX KEY: 0001855175 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 271467257 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 333-5280 MAIL ADDRESS: STREET 1: 10578 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Pipeline Therapeutics, Inc. DATE OF NAME CHANGE: 20210405 4 1 rdgdoc.xml OPTION GRANT X0508 4 2024-05-24 0001855175 Contineum Therapeutics, Inc. CTNM 0001861550 Lorrain Daniel S. 10578 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 1 Chief Scientific Officer 0 Stock Option (right to buy) 15.76 2024-05-24 4 A 0 100000 0 A 2034-05-23 Class A Common Stock 100000 100000 D Stock Option (right to buy) 15.76 2024-05-24 4 A 0 3700 0 A 2034-05-23 Class A Common Stock 3700 3700 I By Spouse Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service. Options granted under the Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service. /s/ Peter Slover, Attorney-in-Fact 2024-05-29